Search research articles
Contact Us
Filters
Showing results (151-160 of 376) with videos related to
Page
of 38
Sort By:
Current Opinion in Lipidology
|
March 16, 2005
Inherited disorders of HDL metabolism and atherosclerosis
G Kees Hovingh, Eric de Groot, Wim van der Steeg, et al.
Atherosclerosis
|
December 31, 2015
Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey
G Kees Hovingh, Shravanthi R Gandra, Jan McKendrick, et al.
Journal of the American College of Cardiology
|
March 25, 2022
Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia
G Kees Hovingh, Ib Christian Klausen, Eli Heggen, et al.
European Journal of Preventive Cardiology
|
July 30, 2025
Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: Results from a randomized trial
Jordan M Kraaijenhof, Merel C Peletier, Nick S Nurmohamed, et al.
The Journal of Antimicrobial Chemotherapy
|
May 10, 2021
Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid
Christoph Dorn, David Petroff, Melanie Stoelzel, et al.
Atherosclerosis
|
November 14, 2021
Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia
Tycho R Tromp, Arjen J Cupido, Laurens F Reeskamp, et al.
BMC Medicine
|
August 10, 2022
Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups
Marios K Georgakis, Rainer Malik, Tom G Richardson, et al.
Journal of Clinical Lipidology
|
September 1, 2016
Children with hypercholesterolemia of unknown cause: Value of genetic risk scores
Barbara Sjouke, Michael W T Tanck, Sigrid W Fouchier, et al.
Journal of Clinical Lipidology
|
April 11, 2017
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
John J P Kastelein, G Kees Hovingh, Gisle Langslet, et al.
Biochimica Et Biophysica Acta
|
August 31, 2011
Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT
Ian Tietjen, G Kees Hovingh, Roshni Singaraja, et al.
Page
of 38
Search research articles
Search
Showing results (151-160 of 376) with videos related to
Sort By:
Page
of 38
Current Opinion in Lipidology
|
March 16, 2005
Inherited disorders of HDL metabolism and atherosclerosis
G Kees Hovingh, Eric de Groot, Wim van der Steeg, et al.
Atherosclerosis
|
December 31, 2015
Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey
G Kees Hovingh, Shravanthi R Gandra, Jan McKendrick, et al.
Journal of the American College of Cardiology
|
March 25, 2022
Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia
G Kees Hovingh, Ib Christian Klausen, Eli Heggen, et al.
European Journal of Preventive Cardiology
|
July 30, 2025
Plasma reduction of apolipoprotein C-III with olezarsen leads to significant reductions in postprandial triglyceride levels: Results from a randomized trial
Jordan M Kraaijenhof, Merel C Peletier, Nick S Nurmohamed, et al.
The Journal of Antimicrobial Chemotherapy
|
May 10, 2021
Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid
Christoph Dorn, David Petroff, Melanie Stoelzel, et al.
Atherosclerosis
|
November 14, 2021
Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemia
Tycho R Tromp, Arjen J Cupido, Laurens F Reeskamp, et al.
BMC Medicine
|
August 10, 2022
Associations of genetically predicted IL-6 signaling with cardiovascular disease risk across population subgroups
Marios K Georgakis, Rainer Malik, Tom G Richardson, et al.
Journal of Clinical Lipidology
|
September 1, 2016
Children with hypercholesterolemia of unknown cause: Value of genetic risk scores
Barbara Sjouke, Michael W T Tanck, Sigrid W Fouchier, et al.
Journal of Clinical Lipidology
|
April 11, 2017
Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia
John J P Kastelein, G Kees Hovingh, Gisle Langslet, et al.
Biochimica Et Biophysica Acta
|
August 31, 2011
Increased risk of coronary artery disease in Caucasians with extremely low HDL cholesterol due to mutations in ABCA1, APOA1, and LCAT
Ian Tietjen, G Kees Hovingh, Roshni Singaraja, et al.
Page
of 38